L3VLUP
ProSign in

GMED in the 13F filings

Globus Medical Inc · CUSIP 379577208

Sector · Medical devices and instrumentsTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Surgical, medical and electromedical devices
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
31 Mar 2024
the date the book describes
Filed
15 May 2024
latest of these filings; the earliest 1 May 2024
Managers listing it
8
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q4 2023 and Q1 2024; 8 listed it in both
Shares listed
14,390,819
combined, among listed positions
Reported value
$772m
combined, at the quarter end

Among the 93 comparable managers: 2 buyers (opened or added shares) and 5 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.

Managers listing GMED in Q1 2024

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q4 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

8 of 8 holders

ActionFiling
Janus Henderson Group Ltd7,662,395$411m0.22%Trimmed-246,43315 May 2024 (the filing on sec.gov)
Wellington Management Group LLP3,249,808$174munder 0.1%Added+337,35415 May 2024 (the filing on sec.gov)
Marshall Wace LLP1,229,440$66m0.10%Trimmed-405,13015 May 2024 (the filing on sec.gov)
Two Sigma Advisers LP730,975$39m0.09%Trimmed-61,40015 May 2024 (the filing on sec.gov)
Two Sigma Investments LP713,315$38m0.09%Trimmed-17,27315 May 2024 (the filing on sec.gov)
Capital World Investors574,500$31munder 0.1%Held014 May 2024 (the filing on sec.gov)
GAMCO Investors Inc139,320$7.5m0.08%Added+61614 May 2024 (the filing on sec.gov)
Baillie Gifford & Co91,066$4.9munder 0.1%Trimmed-9611 May 2024 (the filing on sec.gov)

Largest increases and reductions, by shares

Q4 2023 to Q1 2024, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
12 in Q3 2024 to 10 in Q2 2026

Tracked managers listing it, at least.

01020302014201620182020202220242026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
GMED by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20132$32mn.a.n.a.
Q3 20132$131mn.a.n.a.
Q4 20132$154mn.a.n.a.
Q1 20142$188mn.a.n.a.
Q2 20146$144mn.a.n.a.
Q3 20144$134mn.a.n.a.
Q4 20144$136mn.a.n.a.
Q1 20153$154mn.a.n.a.
Q2 20154$195mn.a.n.a.
Q3 20155$155mn.a.n.a.
Q4 20152$215mn.a.n.a.
Q1 20164$194mn.a.n.a.
Q2 20163$200mn.a.n.a.
Q3 20163$215mn.a.n.a.
Q4 20164$232mn.a.n.a.
Q1 20174$233mn.a.n.a.
Q2 20172$266mn.a.n.a.
Q3 20175$341mn.a.n.a.
Q4 20175$482mn.a.n.a.
Q1 20187$588mn.a.n.a.
Q2 20187$513mn.a.n.a.
Q3 201813$674mn.a.n.a.
Q4 201813$570mn.a.n.a.
Q1 20195$619mn.a.n.a.
Q2 20195$589mn.a.n.a.
Q3 20196$733mn.a.n.a.
Q4 201912$832mn.a.n.a.
Q1 20207$597mn.a.n.a.
Q2 20206$610mn.a.n.a.
Q3 20208$639mn.a.n.a.
Q4 20206$855mn.a.n.a.
Q1 20217$779mn.a.n.a.
Q2 202110$997mn.a.n.a.
Q3 20219$871mn.a.n.a.
Q4 202110$912mn.a.n.a.
Q1 202210$934mn.a.n.a.
Q2 20227$684mn.a.n.a.
Q3 20226$781mn.a.n.a.
Q4 20226$840mn.a.n.a.
Q1 202315$720mn.a.n.a.
Q2 202321$946mn.a.n.a.
Q3 202317$881mn.a.n.a.
Q4 202312$912m57
Q1 20248$772m25
Q2 202413$1.0bn66
Q3 202412$868m56
Q4 202414$1.4bn56
Q1 202513$951m94
Q2 202512$897m101
Q3 202511$765m64
Q4 202513$1.6bn1220
Q1 202614$1.6bn1915
Q2 202610$1.1bn1418

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

GMED and LLY →GMED and JNJ →GMED and VRTX →Choose a stock to compare with GMED →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own GMED, latest filings →Back to the 13F Explorer →